Bio-Rad Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 26, 2023 at 04:15 pm EDT
Share
Bio-Rad Laboratories, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 632.12 million compared to USD 680.8 million a year ago. Net income was USD 106.26 million compared to net loss of USD 162.81 million a year ago. Basic earnings per share from continuing operations was USD 3.65 compared to basic loss per share from continuing operations of USD 5.48 a year ago. Diluted earnings per share from continuing operations was USD 3.64 compared to diluted loss per share from continuing operations of USD 5.48 a year ago.
For the nine months, sales was USD 1,990.08 million compared to USD 2,071.96 million a year ago. Net loss was USD 987.03 million compared to USD 4,455.27 million a year ago. Basic loss per share from continuing operations was USD 33.63 compared to USD 149.41 a year ago. Diluted loss per share from continuing operations was USD 33.63 compared to USD 149.41 a year ago.
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
BIO-RAD LABORATORIES, INC. 
